Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: Therapeutic implications

Anjli Kukreja; Aisha Hutchinson; Amitabha Mazumder; David Vesole; Revathi Angitapalli; Sundar Jagannath; Owen A. O'Connor; Madhav V. Dhodapkar

doi:10.1111/j.1365-2141.2006.06369.x

Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: Therapeutic implications

Anjli Kukreja
, Aisha Hutchinson
, Amitabha Mazumder
, David Vesole
, Revathi Angitapalli
, Sundar Jagannath
, Owen A. O'Connor
, Madhav V. Dhodapkar

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

Recent studies have shown that the interactions between tumour and dendritic cells (DCs) promote clonogenic growth of lymphoproliferative tumours, particularly myeloma. The present study showed that the proteasome inhibitor, bortezomib, disrupts this interaction. Targeting the drug to DCs was required for optimal suppression of tumour growth, including primary myeloma tumour progenitors in clonogenic assays. Bortezomib lead to dose-dependent induction of apoptosis in both myeloid and plasmacytoid DCs, and the sensitivity of DCs to bortezomib was comparable with that of tumour cells. These data suggest that disruption of tumour-DC interactions may contribute to the clinical effects of bortezomib.

Original language	English
Pages (from-to)	106-110
Number of pages	5
Journal	British Journal of Haematology
Volume	136
Issue number	1
DOIs	https://doi.org/10.1111/j.1365-2141.2006.06369.x
State	Published - Jan 2007
Externally published	Yes

Keywords

Lymphoma
Myeloid dendritic cells
Myeloma
Plasmacytoid dendritic cells
Tumour microenvironment

Access to Document

10.1111/j.1365-2141.2006.06369.x

Cite this

@article{21360dbc89774323aacb61659645e3ad,

title = "Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: Therapeutic implications",

abstract = "Recent studies have shown that the interactions between tumour and dendritic cells (DCs) promote clonogenic growth of lymphoproliferative tumours, particularly myeloma. The present study showed that the proteasome inhibitor, bortezomib, disrupts this interaction. Targeting the drug to DCs was required for optimal suppression of tumour growth, including primary myeloma tumour progenitors in clonogenic assays. Bortezomib lead to dose-dependent induction of apoptosis in both myeloid and plasmacytoid DCs, and the sensitivity of DCs to bortezomib was comparable with that of tumour cells. These data suggest that disruption of tumour-DC interactions may contribute to the clinical effects of bortezomib.",

keywords = "Lymphoma, Myeloid dendritic cells, Myeloma, Plasmacytoid dendritic cells, Tumour microenvironment",

author = "Anjli Kukreja and Aisha Hutchinson and Amitabha Mazumder and David Vesole and Revathi Angitapalli and Sundar Jagannath and O'Connor, \{Owen A.\} and Dhodapkar, \{Madhav V.\}",

year = "2007",

month = jan,

doi = "10.1111/j.1365-2141.2006.06369.x",

language = "English",

volume = "136",

pages = "106--110",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma

T2 - Therapeutic implications

AU - Kukreja, Anjli

AU - Hutchinson, Aisha

AU - Mazumder, Amitabha

AU - Vesole, David

AU - Angitapalli, Revathi

AU - Jagannath, Sundar

AU - O'Connor, Owen A.

AU - Dhodapkar, Madhav V.

PY - 2007/1

Y1 - 2007/1

N2 - Recent studies have shown that the interactions between tumour and dendritic cells (DCs) promote clonogenic growth of lymphoproliferative tumours, particularly myeloma. The present study showed that the proteasome inhibitor, bortezomib, disrupts this interaction. Targeting the drug to DCs was required for optimal suppression of tumour growth, including primary myeloma tumour progenitors in clonogenic assays. Bortezomib lead to dose-dependent induction of apoptosis in both myeloid and plasmacytoid DCs, and the sensitivity of DCs to bortezomib was comparable with that of tumour cells. These data suggest that disruption of tumour-DC interactions may contribute to the clinical effects of bortezomib.

AB - Recent studies have shown that the interactions between tumour and dendritic cells (DCs) promote clonogenic growth of lymphoproliferative tumours, particularly myeloma. The present study showed that the proteasome inhibitor, bortezomib, disrupts this interaction. Targeting the drug to DCs was required for optimal suppression of tumour growth, including primary myeloma tumour progenitors in clonogenic assays. Bortezomib lead to dose-dependent induction of apoptosis in both myeloid and plasmacytoid DCs, and the sensitivity of DCs to bortezomib was comparable with that of tumour cells. These data suggest that disruption of tumour-DC interactions may contribute to the clinical effects of bortezomib.

KW - Lymphoma

KW - Myeloid dendritic cells

KW - Myeloma

KW - Plasmacytoid dendritic cells

KW - Tumour microenvironment

UR - https://www.scopus.com/pages/publications/33845496508

U2 - 10.1111/j.1365-2141.2006.06369.x

DO - 10.1111/j.1365-2141.2006.06369.x

M3 - Article

C2 - 17222199

AN - SCOPUS:33845496508

SN - 0007-1048

VL - 136

SP - 106

EP - 110

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 1

ER -

Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: Therapeutic implications

Abstract

Keywords

Access to Document

Fingerprint

Cite this